Towards a coronavirus-based HIV multigene vaccine

Clinical and Developmental Immunology

Volumn 13, Issue 2-4, 2006, Pages 353-360

  Eriksson, Klara K ^a   Makia, Divine ^a   Maier, Reinhard ^a   Ludewig, Burkhard ^a   Thiel, Volker ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

AIDS; Coronavirus; HIV; Vaccination

Indexed keywords

ANTIVIRUS AGENT; CAVEOLIN 1; CHEMOKINE; CIS ACTING ELEMENT; COMPLEMENTARY DNA; CORONAVIRUS VECTOR; DNA VACCINE; GENOMIC RNA; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOSTIMULATING AGENT; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; OLIGONUCLEOTIDE; PROTEINASE; RNA DIRECTED RNA POLYMERASE; STRUCTURAL PROTEIN; TOLL LIKE RECEPTOR; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; ARTICLE; COMMON COLD; CORONAVIRUS; DENDRITIC CELL; DEVELOPING COUNTRY; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; INFECTION PREVENTION; INTESTINE INFECTION; MACROPHAGE; MOLECULAR BIOLOGY; MUCOSAL IMMUNITY; MULTIGENE FAMILY; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REINFECTION; RESPIRATORY TRACT INFECTION; SIGNAL TRANSDUCTION; STRUCTURAL GENE; VACCINATION; VIRAL GENETICS; VIRUS GENE; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; CORONAVIRUS; GENETIC VECTORS; HIV-1; HUMANS;

EID: 33845653452     PISSN: 17402522     EISSN: 10292357     Source Type: Journal    
DOI: 10.1080/17402520600579168     Document Type: Article

References (56)

1. Addo MM, Yu XG, Rathod A, Cohen D, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77:2081-2092.
2. Amara RR, Villinger F, Altman JD, Lydy SL, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
3. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6:200-206.
4. Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, et al. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 7:1320-1326.
5. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, et al. 2001. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 75:11983-11991.
6. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, et al. 2002. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100:1153-1159.
7. Borrow P, Lewicki H, Hahn BH, Shaw GM, et al. 1994. Virusspecific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-6110.
8. Chakravarti DN, Fiske MJ, Fletcher LD, Zagursky RJ. 2000. Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates. Vaccine 19:601-612.
9. Cho BK, Palliser D, Guillen E, Wisniewski J, et al. 2000. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 12:263-272.
10. Coley SE, Lavi E, Sawicki SG, Fu L, et al. 2005. Recombinant mouse hepatitis virus strain A59 from cloned, full-length cDNA replicates to high titers in vitro and is fully pathogenic in vivo. J Virol 79:3097-3106.
11. Crotty S, Lohman BL, Lu FX, Tang S, et al. 1999. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal and cellular immunity. J Virol 73:9485-9495.
12. Davis NL, Caley IJ, Brown KW, Betts MR, et al. 2000. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 74:371-378.
13. Dobbelstein M. 2003. Viruses in therapy - royal road or dead end? Virus Res 92:219-221.
14. Fouts TR, DeVico AL, Onyabe DY, Shata MT, et al. 2003. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 37:129-134.
15. Harvey TJ, Anraku I, Linedale R, Harrich D, et al. 2003. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J Virol 77:7796-7803.
16. Hovanessian AG, Briand JP, Said EA, Svab J, et al. 2004. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 21:617-627.
17. Jin X, Bauer DE, Tuttleton SE, Lewin S, et al. 1999. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991-998.
18. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol 2:251-262.
19. Koup RA, Safrit JT, Cao Y, Andrews CA, et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-4655.
20. Krebs P, Scandella E, Odermatt B, Ludewig B. 2005. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J Immunol 174:4559-4566.
21. Lapenta C, Santini SM, Logozzi M, Spada M, et al. 2003. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198:361-367.
22. Lore K, Betts MR, Brenchley JM, Kuruppu J, et al. 2003. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific T cell responses. J Immunol 171:4320-4328.
23. Lu W, Arraes LC, Ferreira WT, Andrieu JM. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10:1359-1365.
24. Lu W, Wu X, Lu Y, Guo W, et al. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9:27-32.
25. Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM, et al. 2000a. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19:23-32.
26. Ludewig B, Ehl S, Karrer U, Odermatt B, et al. 1998. Dendritic cells efficiently induce protective antiviral immunity. J Virol 72:3812-3818.
27. Ludewig B, Maloy KJ, Lopez-Macias C, Odermatt B, et al. 2000b. Induction of optimal anti-viral neutralizing B cell responses by dendritic cells requires transport and release of virus particles in secondary lymphoid organs. Eur J Immunol 30:185-196.
28. Ludewig B, Oehen S, Barchiesi F, Schwendener RA, et al. 1999. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol 163:1839-1844.
29. Luther SA, Cyster JG. 2001. Chemokines as regulators of T cell differentiation. Nat Immunol 2:102-107.
30. Macatonia SE, Taylor PM, Knight SC, Askonas BA. 1989. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 169:1255-1264.
31. McKay PF, Barouch DH, Schmitz JE, Veazey RS, et al. 2003. Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol 77:4695-4702.
32. McMichael AJ, Hanke T. 2003. HIV vaccines 1983-2003. Nat Med 9:874-880.
33. Moore JP, Cao Y, Qing L, Sattentau QJ, et al. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69:101-109.
34. Moore JP, Parren PW, Burton DR. 2001. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 75:5721-5729.
35. Nonacs R, Humborg C, Tam JP, Steinman RM. 1992. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J Exp Med 176:519-529.
36. Pasternak AO, van den BE, Spaan WJ, Snijder EJ. 2001. Sequence requirements for RNA strand transfer during nidovirus discontinuous subgenomic RNA synthesis. EMBO J 20:7220-7228.
37. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, et al. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176:924-932.
38. Pinto AR, Reyes-Sandoval A, Ertl HC. 2003. Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell Immunol 224:106-113.
39. Pitcher CJ, Quittner C, Peterson DM, Connors M, et al. 1999. HIV-1-specific CD4+ Tcells are detectable inmost individualswith active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5:518-525.
40. Pope M, Haase AT. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9:847-852.
41. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, et al. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
42. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes [in process citation]. Science 283:857-860.
43. Schmitz JE, Kuroda MJ, Santra S, Simon MA, et al. 2003. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 77:2165-2173.
44. Spaan W, Delius H, Skinner M, Armstrong J, et al. 1983. Coronavirus mRNA synthesis involves fusion of non-contiguous sequences. EMBO J 2:1839-1844.
45. Sparwasser T, Koch ES, Vabulas RM, Heeg K, et al. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28:2045-2054.
46. Spira AI, Marx PA, Patterson BK, Mahoney J, et al. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183:215-225.
47. Steinman RM, Pope M. 2002. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519-1526.
48. Summers KL, Hock BD, McKenzie JL, Hart DN. 2001. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am J Pathol 159:285-295.
49. Thiel V, Herold J, Schelle B, Siddell SG. 2001a. Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. J Gen Virol 82:1273-1281.
50. Thiel V, Herold J, Schelle B, Siddell SG. 2001b. Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol 75:6676-6681.
51. Thiel V, Karl N, Schelle B, Disterer P, et al. 2003. Multigene RNA vector based on coronavirus transcription. J Virol 77:9790-9798.
52. Turner BC, Hemmila EM, Beauchemin N, Holmes KV. 2004. Receptor-dependent coronavirus infection of dendritic cells. J Virol 78:5486-5490.
53. Veazey RS, Shattock RJ, Pope M, Kirijan JC, et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9:343-346.
54. Zhu T, Corey L, Hwangbo Y, Lee JM, et al. 2003. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 77:6108-6116.
55. Ziebuhr J, Snijder EJ, Gorbalenya AE. 2000. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 81:853-879.
56. Zinkernagel RM, Ehl S, Aichele P, Oehen S, et al. 1997. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity. Immunol Rev 156:199-209.